Activ-Blister Solutions

Aptar Pharma’s Unidose (UDS) systems are ready-to-use, one-step nasal drug delivery devices that deliver a precise, single dose quickly, easily and reliably. Available for both liquid and powder formulations, our UDS systems are designed to enable the systemic delivery of drugs without the need for injection ...

Aptar Pharma’s nasal vaccine solutions provide a convenient, pain-free nasal vaccine delivery, quickly, precisely and reliably.Renowned for our large and comprehensive range of nasal drug delivery devices and services, our intranasal concept solutions offer reproducible dosing, convenience and ease-of-use for...

Aptar Pharma’s Bidose (BDS) device is a two-shot, robust, primeless, easy-to-use system offering one-handed actuation and precise nasal drug delivery.

Available for liquid formulations, our BDS is designed to enable the systemic delivery of drugs without the need for injection or administration by ...

Aptar Pharma offers a broad range of innovative digital healthcare solutions for the prevention, diagnosis and treatment of diseases, including patient monitoring and healthcare management. All of our digital healthcare solutions are patient friendly, easy to use, intuitive and available as fully integrated t...

Aptar Pharma’s Breath Activated Inhaler (BAI), used in conjunction with a pressurized metered dose inhaler (pMDI), reduces patient variability and patient coordination errors. By doing so, BAI helps improve compliance and adherence in patients with asthma and COPD.

Our BAI also incorporates a c...

Designed for ease of use, reliability and accuracy, Aptar Pharma’s e-Dose Counter technology is designed to support better patient compliance in asthma and COPD patients.

Aptar Pharma’s Airless Drug Delivery Systems provide airtight solutions to protect sensitive dermal formulations across a wide range of viscosities. With the largest and most comprehensive standard range on the market, including over 50 Pharma references worldwide, our proven Airless dispensing solutions offe...

Aptar Pharma’s Bag-on-Valve (BOV) Technology Platform delivers superior continuous dispensing and offers the widest range of portfolio options enabling pure, safe and flexible product applications.

Superior aerosol dispensing format for clean, convenient and safe applicationAptar Pharma’s Bag-on-Valve ...

Our Ophthalmic Squeeze Dispenser is the leading device for preservative-free prescription and over-the-counter products. Featuring unrivaled microbiological safety and a proven track record with more than 250 market references worldwide, it is the only FDA-reviewed technology for multidose, preservative-free ...

Aptar Pharma’s CPS spray pump is a superior technology platform for precise, reliable and targeted preservative-free nasal drug delivery.

Aptar Pharma’s Prohaler® is a high performance, pre-metered multi-dose DPI for optimal patient compliance in the treatment of asthma and COPD and other pulmonary treatments. It uses patient-centric testing and designs to provide the ultimate solution to patient adherence when treating these chronic respirator...

Our DF30 metering valve platform is the industry Gold standard valve technology to deliver safe and repeatable medication to patients with life threatening pulmonary diseases.
The Gold standard metering valves for HFA pMDIsOur DF30 metering valve platform has been the industry gold standard for decades a...

The pharma packaging and drug device industry is constantly evolving to optimise drug delivery, keep up with medical advances and ensure regulatory compliance. Trends like sustainability, cost-efficiency and digitisation continue to shape the sector, and the COVID-19 pandemic remains a challenge.  

Today, there are three marketed nasal vaccines available for human use but many more are in development for both human and veterinary use.Nasal vaccination provides an alternative to the more conventional Injectable drug delivery system. Mucosal immunity can develop via interaction with immune modulators present in the nasal cavity, where the nasal associated lymphoid tissue (NALT) region plays a dominant role

The innovative, easy-to-use connected drug delivery device and companion mobile app will contribute to improving dose compliance and adherence, thus optimizing patient treatment outcomes.

Ophthalmic diseases such as Age-related Macular Degeneration (AMD) and Glaucoma are potentially chronic conditions, requiring life-long medical therapy. Failure by the patient to adhere to a proper treatment regimen may lead to disease progression and visual loss, in addition to all of the consequences around quality of life and capacity to work.

Aptar Pharma’s patented Cartridge Pump System (CPS), was recently reviewed by the U.S. FDA as the drug delivery device in the approval of Oyster Point Pharma’s TYRVAYA™ (varenicline solution) Nasal Spray 0.03 mg, the first and only nasal spray approved for the treatment of the signs and symptoms of dry eye disease.

PureHale Technology Platform

Better Breathing Made Easy

Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, and i2c Pharmaceutical Services, a leading service provider for the development of pharmaceutical formulations, today announced an exclusive partnership to co-develop and promote i2c’s patented pressurized metered dose inhaler (pMDI) technology, Respitab®.

We design, develop and manufacture a comprehensive range of innovative and patient-focused drug delivery systems, services and proven solutions for the widest range of biotechnology, healthcare and pharmaceutical applications.

Aptar announced today that following the entry into exclusive negotiations with Voluntis (ENXTPA: ALVTX) on June 21, 2021, and after completion of the consultation procedure of the employee representative bodies of Voluntis, it has signed on July 22, 2021 a share purchase agreement for the acquisition...

Our specialist analytical, laboratory and regulatory services add value at every stage of the drug development process, accelerating and de-risking your program along the way.

Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, announced that they have entered into an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ proprietary high payload dry powder inhaler, Orbital.

In these short interviews, Sai Shankar, Adam Shain and Marcus Bates discuss the full potential of connectivity, coronavirus as a potential accelerator of adoption, and the place of connected drug delivery systems within Aptar Pharma’s broader offering to industry.

If you’re looking for news, product information and market trends from leading pharma companies, the CPHI-Online.com Company Showcases are a great resource for buyers who want to stay up to date, browse product portfolios and find the right partner.

A review on how the use of propellants in pressurized metered dose inhalers has evolved and how alternative propellants, such as more environmentally friendly propellants, could be a catalyst for greater patient adherence.

The collaboration will focus on bringing together connected drug delivery devices and the digital platform for asthma and COPD in China and other Asian markets.

Aptar Pharma thrives on transforming ideas into commercial opportunities, bringing drug delivery solutions to market for customers around the world. Discover how we can help you with your next drug delivery challenge.

The single-use, ready-to-use, one-step nasal delivery device can deliver a formulation in an emergency situation quickly and easily.

Discover why Aptar Pharma is the go-to drug delivery expert. Our life-life virtual booth is rich in content, featuring 3D products, multi-media videos, brochures, scientific publications and more for you to experience. Hover your mouse cursor over the colored circle hotspots to uncover and interact with our broad range of complete product and service solutions. Enjoy an enhanced virtual visitor experience, and be sure to book a meeting with one of our Aptar Pharma experts to find out how we can help you solve your next drug delivery challenge. To visit our virtual booth, click the “Download” button

Acquisition reflects movement of treatments being administered by patients at home rather than by healthcare providers.

This webinar originally aired as part of CPHI Discover - 17-28 May 2021 Nasal spray drug delivery can provide significant advantages over traditional approaches to vaccine administration. In this session, hear from Aptar Pharma and Vaccine Market Review on nasal physiology and Vaccine targets.  This session will serve as an introduction to Aptar Pharma and Vaccine Market Review nasal physiology and vaccine targets. Discussion points include: Overview of intranasal formulations Review nasal vaccine Opportunities Aptar Pharma device offerings

AptarGroup, Inc. (NYSE: ATR), a global leader in consumer dispensing, active packaging and drug delivery solutions, announced today that it has acquired Noble International, a leader in drug delivery training devices and patient onboarding.

This webinar originally aired as part of CPHI Discover - 17-28 May 20211. Drug repurposing has gained traction in the past year amidst the COVID-19 vaccine race - what are the challenges & potential benefits of drug repurposing, compared to the traditional drug development process? What is drug repurposing? Benefits to the development process- speed to market, risk, costs Advantages of nasal delivery and the challenges of repurposing Patient benefits -Our track record and case study Case Study: Repurposing Generic Drugs for COVID-19 and Cancer Using AI-Powered Technology

The system protects oral solid drug products with a 3-Phase Activ-Polymer solution that is fully integrated into the blister package.

There are several key strategic decisions to be made in the rapid development process of COVID-19 vaccines and treatments, including where to target the drug delivery, the appropriate formulation, the correct device and the best regulatory pathway. This webinar discusses these challenges for nasal and pulmonary drug delivery.

Provides migraine sufferers with a convenient, patient-friendly delivery approach.

The industry’s first cordless, ready-to-use, nebulizer-like system

PureHale™ is a cordless, nebulizer-like device that comes pre-filled and allows users to relieve their symptoms wherever and whenever needed.

Aptar’s nasal Unidose device - the result of a 10-year customer collaboration - marks the first FDA approval of a prescription drug using the company’s patented Unidose Powder System.

Aptar Pharma’s Ophthalmic Squeeze Dispenser is the leading device for preservative-free prescription and over-the-counter products. Featuring unrivaled microbiological safety and a proven track record with more than  300 market references worldwide, it is the only FDA-reviewed technology for multidose, preservative-free systems in eye care

Aptar Pharma, a leading drug delivery systems provider, will host a live educational webinar reviewing new methodologies in assessing CNS drug deliveries. Taking place on July 17 at 3pm GMT, the webinar, entitled “New Tools to advance CNS Drug Delivery”, will be hosted by Dr. Julie D. Suman, President of Next Breath, an Aptar Pharma business, and Dr. Philip Kuehl, Senior Scientist, Lovelace Biomedical.

When patients self-administer their medications, 60% do not take them as intended and over half of all patients are non-adherent. The resulting cost of non-adherence and non-optimized therapy is steep and everyone pays the price, from Pharmaceutical companies and payers to HCPs and their patients. The cost of non-adherence alone is US$300 billion per year with $188 billion of US pharma revenue lost. Aptar provides a broad range of Digital Healthcare disease management solutions that are ideal for patients who will self-administer their medications. Our technology has the potential to augment patient care, deliver value across the digital health ecosystem and deliver better patient outcomes providing a more seamless engagement for HCPs, payers, and our Pharma partners in a more connected future.This webinar originally aired as part of Pharmapack Europe 2021

PureHale is valuable to pharmaceutical partners seeking a system that can carry a range of formulations and comes in various container sizes.

PureHale is a new portable drug delivery device designed for upper respiratory care.

Approval expands the regulatory acceptance of Aptar Pharma’s OSD as an approved delivery system for preservative-free eye care formulations.